Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients

(2020) Peter Alping et al.   ANNALS OF NEUROLOGY

CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date

(2019) Mihai Ancau et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature

(2019) Chiara Zanetta et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

B-cell Therapy for Multiple Sclerosis: Entering an era

(2018) Ariele L. Greenfield et al.   ANNALS OF NEUROLOGY

Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland

(2018) Barbara Scotti et al.   PLoS One

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

The temporal impact of aging on the burden of herpes zoster

(2017) Lijoy Varghese et al.   BMC Geriatrics

Rituximab associated late-onset neutropenia—a rheumatology case series and review of the literature

(2016) William E. Monaco et al.   CLINICAL RHEUMATOLOGY

The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches

(2016) Pankita H. Pandya et al.   Journal of Immunology Research

Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients

(2014) Arumugam Palanichamy et al.   JOURNAL OF IMMUNOLOGY

Four cases of rituximab-associated melanoma

(2014) Charles Velter et al.   MELANOMA RESEARCH

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

(2014) P. S. Sorensen et al.   NEUROLOGY

CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination

(2014) Janet E. Holley et al.   Multiple Sclerosis and Related Disorders

Neutrophil cell surface receptors and their intracellular signal transduction pathways

(2013) Krisztina Futosi et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

A Survey of the FAERS Database Concerning the Adverse Event Profiles of α1-Adrenoreceptor Blockers for Lower Urinary Tract Symptoms

(2013) Koji Yoshimura et al.   International Journal of Medical Sciences

Data Mining of the Public Version of the FDA Adverse Event Reporting System

(2013) Toshiyuki Sakaeda et al.   International Journal of Medical Sciences

B-cell biology and development

(2013) Kathrin Pieper et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

(2013) Christian Klein et al.   mAbs

Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database

(2011) Jean-Louis Montastruc et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Multiple Sclerosis: Pathogenesis and Treatment

(2011) Ingrid Loma et al.   Current Neuropharmacology

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

(2010) Stephen A. Beers et al.   SEMINARS IN HEMATOLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Humoral and Cellular Immunity to Varicella‐Zoster Virus: An Overview

(2008) Ann M. Arvin   JOURNAL OF INFECTIOUS DISEASES

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE